Human leukocyte antigen type and posttransplant lymphoproliferative disorder

Transplantation

Volumn 99, Issue 6, 2015, Pages 1220-1225

  Lustberg, Mark E ^a   Pelletier, Ronald P ^a   Porcu, Pierluigi ^a,b   Martin, Stanley I ^a   Quinion, Carl D ^b   Geyer, Susan M ^a   Caligiuri, Michael A ^a,b   Baiocchi, Robert A ^a,b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA B40 ANTIGEN; HLA B8 ANTIGEN; HLA ANTIGEN;

ADULT; AFRICAN AMERICAN; ARTICLE; BONE MARROW; CENTRAL NERVOUS SYSTEM; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE PREDISPOSITION; EPSTEIN BARR VIRUS; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; T LYMPHOCYTE; ADVERSE EFFECTS; CASE CONTROL STUDY; COMPLICATION; EPIDEMIOLOGY; EPSTEIN BARR VIRUS INFECTION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPHOPROLIFERATIVE DISORDERS; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RETROSPECTIVE STUDY; UNITED STATES;

ADULT; CASE-CONTROL STUDIES; COHORT STUDIES; DISEASE SUSCEPTIBILITY; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HLA-B40 ANTIGEN; HLA-B8 ANTIGEN; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; OHIO; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84930540734     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000487     Document Type: Article

References (49)

1. BabelN, Vergopoulos A, Trappe RU, et al. Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients. Transplantation. 2007;84:387.
2. Caillard S, Lelong C, Pessione F, et al. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry. Am J Transplant. 2006;6:2735.
3. Knight JS, Tsodikov A, Cibrik DM, et al. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol. 2009;27:3354.
4. Buadi FK, Heyman MR, Gocke CD, et al. Treatment and outcomes of post-transplant lymphoproliferative disease: A single institution study. Am J Hematol. 2007;82:208.
5. Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: A report of 24 cases observed in a single center. J Clin Oncol. 1995;13:961.
6. Ciancio G, Siquijor AP, Burke GW, et al. Post-transplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era. Clin Transplant. 1997;11:243.
7. Bates WD, Gray DW, Dada MA, et al. Lymphoproliferative disorders in Oxford renal transplant recipients. J Clin Pathol. 2003;56:439.
8. Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol. 2010;28:1038.
9. Caillard S, Porcher R, Provot F, et al. Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. J Clin Oncol. 2013;31:1302.
10. Rezk SA, Weiss LM. Epstein-Barr virus-Associated lymphoproliferative disorders. Hum Pathol. 2007;38:1293.
11. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet. 1964;1:702.
12. Epstein MA, Barr YM. Cultivation in vitro of human lymphoblasts from Burkitt's malignant lymphoma. Lancet. 1964;1:252.
13. Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood. 2007;110:972.
14. d'Amore F, Johansen P, Houmand A, et al. Epstein-Barr virus genome in non-Hodgkin's lymphomas occurring in immunocompetent patients: highest prevalence in nonlymphoblastic T-cell lymphoma and correlation with a poor prognosis. Danish Lymphoma Study Group, LYFO. Blood. 1996;87:1045.
15. Porter DD, Wimberly I, Benyesh-Melnick M. Prevalence of antibodies to EB virus and other herpesviruses. JAMA. 1969;208:1675.
16. Gerber P, Whang-Peng J, Monroe JH. Transformation and chromosome changes induced by Epstein-Barr virus in normal human leukocyte cultures. Proc Natl Acad Sci U S A. 1969;63:740.
17. Gerber P, Whang-Peng J, Monroe JH. Lymphoproliferative effect of Epstein-Barr virus on normal human lymphocytes in cultures. Bibl Haematol. 1970:739.
18. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood. 2006;107:3053.
19. Choquet S, Oertel S, LeBlond V, et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol. 2007;86:599.
20. Sundin M, Le Blanc K, Ringden O, et al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica. 2006;91:1059.
21. Morrison VA, Dunn DL, Manivel JC, et al. Clinical characteristics of posttransplant lymphoproliferative disorders. Am J Med. 1994;97:14.
22. Opelz G, Dohler B. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant. 2004;4:222.
23. van LeeuwenMT, Grulich AE, Webster AC, et al. Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood. 2009;114:630.
24. VanBuskirk AM, Malik V, Xia D, et al. A gene polymorphism associated with posttransplant lymphoproliferative disorder. Transplant Proc. 2001;33:1834.
25. Dierksheide JE, Baiocchi RA, Ferketich AK, et al. IFN-gamma gene polymorphisms associate with development of EBV + lymphoproliferative disease in hu PBL-SCID mice. Blood. 2005;105:1558.
26. Lee TC, Savoldo B, Barshes NR, et al. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clin Transplant. 2006;20:389.
27. Bogunia-Kubik K, Mlynarczewska A, Jaskula E, et al. The presence of IFNG 3/3 genotype in the recipient associates with increased risk for Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2006;132:326.
28. Babel N, Cherepnev G, Kowalenko A, et al. Nonimmunologic complications and gene polymorphisms of immunoregulatory cytokines in long-term renal transplants. Kidney Int. 2004;66:428.
29. McAulay KA, Haque T, Crawford DH. Tumour necrosis factor gene polymorphism: A predictive factor for the development of post-transplant lymphoproliferative disease. Br J Cancer. 2009;101:1019.
30. Wheless SA, Gulley ML, Raab-Traub N, et al. Post-transplantation lymphoproliferative disease: Epstein-Barr virus DNA levels, HLA-A3, and survival. Am J Respir Crit Care Med. 2008;178:1060.
31. Montone KT, Litzky LA, Wurster A, et al. Analysis of Epstein-Barr virusassociated posttransplantation lymphoproliferative disorder after lung transplantation. Surgery. 1996;119:544.
32. Pourfarziani V, Einollahi B, Taheri S, et al. Associations of Human Leukocyte Antigen(HLA) haplotypes with risk of developing lymphoproliferative disorders after renal transplantation. Ann Transplant. 2007;12:16.
33. Hjalgrim H, Rostgaard K, Johnson PC, et al. HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBVrelated Hodgkin lymphoma. Proc Natl Acad Sci U S A. 2010;107:6400.
34. Brennan RM, Burrows SR. A mechanism for the HLA-A∗01-Associated risk for EBV + Hodgkin lymphoma and infectious mononucleosis. Blood. 2008;112:2589.
35. Niens M, Jarrett RF, Hepkema B, et al. HLA-A∗02 is associated with a reduced risk and HLA-A∗01 with an increased risk of developing EBV + Hodgkin lymphoma. Blood. 2007;110:3310.
36. Aissani B, Ogwaro KM, Shrestha S, et al. The major histocompatibility complex conserved extended haplotype 8. 1 in AIDS-related non-Hodgkin's lymphoma. J Acquir Immune Defic Syndr. 2009;52:170-179.
37. Stern M, Opelz G, Dohler B, et al. Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma. Blood. 115;3960.
38. Subklewe M, Marquis R, Choquet S, et al. Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation. Transplantation. 2006;82:1093.
39. Reshef R, LuskinMR, Kamoun M, et al. Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients. Am J Transplant. 2011;11:817.
40. Chu PG, Chang KL, Chen WG, et al. Epstein-Barr virus(EBV) nuclear antigen(EBNA)-4 mutation in EBV-Associated malignancies in three different populations. Am J Pathol. 1999;155:941.
41. de Campos-Lima PO, Gavioli R, Zhang QJ, et al. HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. Science. 1993;260:98.
42. Midgley RS, Bell AI, Yao QY, et al. HLA-A11-restricted epitope polymorphism among Epstein-Barr virus strains in the highly HLA-A11-positive Chinese population: incidence and immunogenicity of variant epitope sequences. J Virol. 2003;77:11507.
43. Bell MJ, Brennan R, Miles JJ, et al. Widespread sequence variation in Epstein-Barr virus nuclear antigen 1 influences the antiviral T cell response. J Infect Dis. 2008;197:1594.
44. McAulay KA, Higgins CD, Macsween KF, et al. HLA class I polymorphisms are associated with development of infectious mononucleosis upon primary EBV infection. J Clin Invest. 2007;117:3042.
45. Kekik C, Besisik SK, Seyhun Y, et al. Relationship between HLA tissue type, CMV infection, and acute graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: single-center experience. Transplant Proc. 2009;41:3859.
46. Tseng KC, Chang CK, Chou AL, et al. Prognostic effect of human leukocyte antigen class I and II alleles on chronic hepatitis C patients treated by pegylated interferon-Alfa plus ribavirin in Taiwan. Hepatogastroenterology. 2010;57:456.
47. Farag RE, Arafa MM, El-Etreby S, et al. Human leukocyte antigen class I alleles can predict response to pegylated interferon/ribavirin therapy in chronic hepatitis C Egyptian patients. Arch Iran Med. 2013;16:68.
48. Dai CY, ChuangWL, HsiehMY, et al. Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitisC patients. Antiviral Res. 2010;85:396.
49. Cho MC, Park CJ, Huh J, et al. Bone marrow findings of 23 Korean posttransplant lymphoproliferative disorder patients: A single-center experience. Clin Transplant. 2012.